[go: up one dir, main page]

ME03807B - Jedinjenja indol karboksamida korisna kao inhibitori kinaze - Google Patents

Jedinjenja indol karboksamida korisna kao inhibitori kinaze

Info

Publication number
ME03807B
ME03807B MEP-2020-158A MEP2020158A ME03807B ME 03807 B ME03807 B ME 03807B ME P2020158 A MEP2020158 A ME P2020158A ME 03807 B ME03807 B ME 03807B
Authority
ME
Montenegro
Prior art keywords
carboxamide
fluoro
acryloyl
indole
dimethyl
Prior art date
Application number
MEP-2020-158A
Other languages
German (de)
English (en)
French (fr)
Inventor
Saleem Ahmad
Andrew J Tebben
Hua Gong
Qingjie Liu
Khehyong Ngu
Scott Hunter Watterson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ME03807B publication Critical patent/ME03807B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (8)

1. Jedinjenje sa Formulom (1): ili so istog, gde:X je CR4;A je: ili Q2 je -C(O)CH=CH2, -C(O)CH=CHCH2N(CH3)2, -C(O)C=CR7, -C(O)C=C(C1-3hidroksialkil), -C(O)C=C(fenil), -C(O)C=CSi(CH3)3, ili -S(O)2CH=CH2;R1 je H, -CH3, -CF3, ili fenil supstituisan sa nula ili 1 R12;R2 je H, -CH3, ciklopropil, ili fenil supstituisan sa nula ili 1 R12, pod uslovom da najmanje jedan od R1 i R2 je -CH3;R3 je F ili Cl; R4 je H ili F;R6 je H, F, Cl, -CF3, ili C1-3 alkoksi;R7, pri svakom pojavljivanju, je nezavisno H, C1-4 alkil, ili ciklopropil; iR12 je F, Cl, -CN, -CF3, ili C1-3 alkoksi.
2. Jedinjenje prema patentnom zahtevu 1 ili so istog, gde: R6je H ili F;iQ2 je -C(O)CH=CH2, -S(O)2CH=CH2, -C(O)CH=CHCH2N(CH3)2, -C(O)C=CH, - C(O)C=CCH3, -C(O)C=CCH2CH3, -C(O)C=CCH2CH2CH3, -C(O)C=C(CH3)2OH, - C(O)C=CSi(CH3)3, -C(O)C=C(ciklopropil), ili -C(O)C=C(fenil).
3. Jedinjenje prema patentnom zahtevu 1 koje ima strukturu:
4. Jedinjenje prema patentnom zahtevu 1 ili so istog, gde navedeno jedinjenje je odabrano od: (RS)-4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-5-fluoro-2,3-dimetil-1H-indol-7- karboksamida (95); 4-(1-akriloil-1,2,3,4-tetrahidrohinolin-6-il)-5-fluoro-2,3-dimetil-1H-indol-7- karboksamida (97); 4-(1-akriloil-1,2,3,4-tetrahidrohinolin-7-il)-5-fluoro-2,3-dimetil-1H-indol-7- karboksamida (99); (RS)-4-(4-akriloil-3,4-dihidro-2H-benzo[b][1,4]oksazin-8-il)-5-fluoro-2,3- dimetil-1H-indol-7-karboksamida (102); 4-(2-(but-2-inoil)-1,2,3,4-tetrahidroizohinolin-5-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida (129); 4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-7- il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida (131); 4-(2-(but-2-inoil)-1,2,3,4- tetrahidroizohinolin-7-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida (134); 4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida, pojedinačnih enantiomera (153 i 154); 4-(4-akriloil-3,4-dihidro-2H-benzo[b][1,4]oksazin-8-il)-5-fluoro-2,3-dimetil-1H-indo1-7-karboksamida, pojedinacnih enantiomera (155 i 156); 4-(2-akriloil-4-fluoro-1,2,3,4-tetrahidroizohinolin-5-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida, pojedinačnih diastereomera (169 do 172); (RS)-4-(5-akriloil-2,3,4,5-tetrahidrobenzo[b][1,4]oksazepin-9-il)-5- fluoro-2,3-dimetil-1H-indol-7-karboksamida (186); 4-(5-akriloil-2,3,4,5- tetrahidrobenzo[b][1,4]oksazepin-9-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida, pojedinačnih enantiomera (187 i 188); (RS)-4-(2-akriloil-7-fluoro-1,2,3,4-tetrahidroizohinolin-5- il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida (189); 4-(2-akriloil-7-fluoro-1,2,3,4- tetrahidroizohinolin-5-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida, pojedinačnih enantiomera (190 i 191); 4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-6-il)-5-fluoro-2,3-dimetil-1H indol-7-karboksamida (192); (RS)-4-( 4-akriloil-3,4-dihidro-2H-benzo[b][1,4]tiazin-8-il)-5- fluoro-2,3-dimetil-1H-indol-7-karboksamida (194); 4-(4-akriloil-3,4-dihidro-2H benzo[b][1,4]tiazin-8-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida, pojedinačnih enantiomera (195 i 196); (RS)-4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-5-fluoro-3-metil-2- (trifluorometil)-1H-indol-7-karboksamida (197); 4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-5-fluoro-3-metil-2-(trifluorometil)-1H-indol-7-karboksamida, pojedinacnih enantiomera (198 i 199); 4-(2-(but-2-inoil)-1,2,3,4-tetrahidroizohinolin-6-il)-5-fluoro-2,3-dimetil-1H-indol-7- karboksamida (203); (RS)-4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-8-il)-5-fluoro-2,3-dimetil-1H-indol-7-karboksamida (204); 4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-8-il)-5-fluoro-2,3- dimetil-1H-indo1-7-karboksamida, pojedinacnih enantiomera (205 i 206); (RS)-4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-3-ciklopropil-5-fluoro-2-metil-1H-indol-7-karboksamida (209);4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-3-ciklopropil-5-fluoro-2-metil-1H-indol-7-karboksamida, pojedinacnih enantiomera (210 211); (RS)-4-(2-akriloil-1,2,3,4- tetrahidroizohino1in-5-il)-5-fluoro-3-(4-fluorofenil)-2-metil-1H-indo1-7-karboksamida (212); 4- (2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-5-fluoro-3-(4-fluorofenil)-2-metil-1H-indo1-7- karboksamida, pojedinacnih enantiomera (213 214); (RS)-4-(2-akriloil-1,2,3,4- tetrahidroizohinolin-5-il)-5-fluoro-2-(4-fluorofenil)-3-metil-1H-indol-7-karboksamida (215); 4-2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-5-hloro-2,3-dimetil-1 H-indol-7-karboksamida (239);4-(2-akriloil-1,2,3,4-tetrahidroizohinolin-5-il)-5-hloro-2,3-dimetil-1H-indol-7-karboksamida, pojedinacnih atropizomera (240 i 264); i 4-(2-(but-2-inoil)-1,2,3,4-tetrahidroizohinolin-5-il)-5- hloro-2,3-dimetil-1H-indol-7-karboksamida (265).
5. Farmaceutska kompozicija koja sadrži jedinjenje prema bilo kom od patentnih zahteva 1-4 ili farmaceutski-prihvatljivu so istog; i farmaceutski prihvatljiv nosač.
6. Jedinjenje prema bilo kom od patentnih zahteva 1-4 ili farmaceutski-prihvatljiva so istog, za primenu u terapiji u lečenju autoimune bolesti ili hronične inflamatorne bolesti.
7. Jedinjenje ili farmaceutski prihvatljiva so istog za primenu prema patentnom zahtevu 6 gde navedena autoimuna bolest ili hronična inflamatorna bolest je odabrana od sistemskog eritemskog lupusa (SLE), reumatoidnog artritisa, multiple skleroze (MS), i Sjogren-ovog sindroma.
8. Jedinjenje prema bilo kom od patentnih zahteva 1-4, ili so istog, za primenu u terapiji.
MEP-2020-158A 2014-10-24 2015-10-23 Jedinjenja indol karboksamida korisna kao inhibitori kinaze ME03807B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068225P 2014-10-24 2014-10-24
EP18205411.4A EP3461821B1 (en) 2014-10-24 2015-10-23 Indole carboxamide compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
ME03807B true ME03807B (me) 2021-04-20

Family

ID=54427877

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2020-158A ME03807B (me) 2014-10-24 2015-10-23 Jedinjenja indol karboksamida korisna kao inhibitori kinaze
MEP-2020-102A ME03740B (me) 2014-10-24 2020-12-17 Jedinjenja indol karboksamida korisna kao inhibitori kinaze

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2020-102A ME03740B (me) 2014-10-24 2020-12-17 Jedinjenja indol karboksamida korisna kao inhibitori kinaze

Country Status (35)

Country Link
US (8) US9688629B2 (me)
EP (2) EP3209656B1 (me)
JP (1) JP6517928B2 (me)
KR (2) KR102030305B1 (me)
CN (2) CN107108583B (me)
AR (2) AR102426A1 (me)
AU (2) AU2015335694B2 (me)
CA (1) CA2965517C (me)
CL (1) CL2017000992A1 (me)
CO (1) CO2017004481A2 (me)
CY (2) CY1123401T1 (me)
DK (2) DK3461821T3 (me)
EA (2) EA032277B1 (me)
ES (2) ES2809974T3 (me)
HR (2) HRP20200819T1 (me)
HU (2) HUE050706T2 (me)
IL (2) IL251797B (me)
LT (2) LT3209656T (me)
MA (2) MA47043B1 (me)
ME (2) ME03807B (me)
MX (2) MX393057B (me)
MY (2) MY188048A (me)
PE (2) PE20190710A1 (me)
PH (2) PH12017500725B1 (me)
PL (2) PL3209656T3 (me)
PT (2) PT3461821T (me)
RS (2) RS60312B1 (me)
SG (3) SG11201703188QA (me)
SI (2) SI3461821T1 (me)
SM (2) SMT202000317T1 (me)
TN (2) TN2017000119A1 (me)
TW (2) TWI743401B (me)
UY (1) UY36371A (me)
WO (1) WO2016065226A1 (me)
ZA (1) ZA201804893B (me)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143768A1 (en) 2013-03-15 2014-09-18 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
ES2942723T3 (es) 2014-04-23 2023-06-06 Incyte Holdings Corp 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET
SG11201703187PA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Carbazole derivatives
SMT202100082T1 (it) 2014-10-24 2021-03-15 Takeda Pharmaceuticals Co Composti eteroarilici per il trattamento di malattie oftalmiche
US10023534B2 (en) 2014-10-24 2018-07-17 Bristol-Myers Squibb Company Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
KR20250163425A (ko) 2016-06-20 2025-11-20 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
RS61285B1 (sr) * 2016-09-02 2021-02-26 Bristol Myers Squibb Co Proces pripreme jedinjenja indol karboksamida
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
BR112020016466A2 (pt) 2018-02-13 2020-12-15 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1, para tratar câncer e para aprimorar a função de células-t em pacientes com hepatite b crônica (chb), e, kit para tratar ou prevenir câncer ou uma doença ou condição.
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
AU2019301811B2 (en) * 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112424207B (zh) 2018-07-25 2024-03-19 诺华股份有限公司 Nlrp3炎性小体抑制剂
WO2020028258A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
MX2022006052A (es) * 2019-11-22 2022-08-15 Univ California Inhibidores de la caspasa 6 y usos de los mismos.
JP2023505155A (ja) * 2019-12-04 2023-02-08 アプティニックス インコーポレイテッド 神経変性疾患に関連する認知障害を治療する方法
WO2021247748A1 (en) * 2020-06-02 2021-12-09 Gb005, Inc. Kinase inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2021323300B2 (en) * 2020-08-07 2025-12-18 Shanghai Meiyue Biotech Development Co., Ltd. Complement factor B inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
US20230265083A1 (en) * 2020-08-10 2023-08-24 Prelude Therapeutics Incorporated Heterocycle CDK Inhibitors And Their Use Thereof
BR112023002031A2 (pt) 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
WO2022089620A1 (zh) * 2020-10-30 2022-05-05 苏州晶云药物科技股份有限公司 吲哚基甲酰胺类化合物的新晶型及其制备方法
EP4277893A1 (en) * 2021-01-12 2023-11-22 GB005, Inc. Indole derivatives as kinase inhibitors
CN114957241B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 杂环类化合物作为激酶抑制剂的制备及其应用
CN114853723B (zh) * 2021-02-03 2023-11-24 药雅科技(上海)有限公司 吲哚类化合物btk抑制剂的制备及其应用
CN115141176B (zh) * 2021-03-31 2023-08-22 药雅科技(上海)有限公司 炔代吲哚类fgfr抑制剂及其制备方法和用途
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
US20240383871A1 (en) 2021-08-30 2024-11-21 Bristol-Myers Squibb Company Compound useful for pet-imaging of bruton’s tyrosine kinase
WO2023227080A1 (zh) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 一种protac化合物、含其的药物组合物及其制备方法和应用
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN115010665A (zh) * 2022-08-05 2022-09-06 山东省食品药品检验研究院 一种硫酸特布他林杂质b的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
CN101060842A (zh) * 2004-09-21 2007-10-24 葛兰素集团有限公司 化合物
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2008519843A (ja) 2004-11-10 2008-06-12 シージーアイ ファーマスーティカル インコーポレーテッド 特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法
EP1831227B1 (en) 2004-12-17 2013-06-19 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
EP1863766B1 (en) 2005-03-10 2015-05-20 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
US20090275570A1 (en) 2005-04-06 2009-11-05 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
KR20080021077A (ko) * 2005-06-30 2008-03-06 스미스클라인 비참 코포레이션 화합물
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2006316322B2 (en) 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
TWI387585B (zh) 2006-09-01 2013-03-01 Dow Agrosciences Llc 殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺
EP2068849A2 (en) 2006-09-11 2009-06-17 CGI Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
AU2007297221B2 (en) 2006-09-11 2012-11-08 Mylan Laboratories Limited Dibenzofuran derivatives as inhibitors of PDE-4 and PDE-10
PL2529621T3 (pl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
US8188272B2 (en) 2007-03-21 2012-05-29 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
JP2010525046A (ja) 2007-04-27 2010-07-22 アストラゼネカ アクチボラグ 血液系腫瘍の治療のための方法
WO2008144253A1 (en) * 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
AU2008335761B2 (en) 2007-12-13 2014-04-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
HUE058352T2 (hu) 2008-02-14 2022-07-28 Lilly Co Eli Új képalkotó szerek neurológiai diszfunkció kimutatására
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
US8476430B2 (en) 2008-07-24 2013-07-02 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
JP5487214B2 (ja) * 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
ES2733093T3 (es) 2009-02-13 2019-11-27 Nextivity Inc Control remoto para amplificador
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2789614B1 (en) 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
US9062028B2 (en) 2011-04-28 2015-06-23 Bristol-Myers Squibb Company Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
KR101585753B1 (ko) 2011-05-17 2016-01-14 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
KR20140058543A (ko) * 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
ES2660210T3 (es) * 2012-09-07 2018-03-21 Novartis Ag Derivados de indolcarboxamida y usos de los mismos
CN105473573B (zh) 2013-06-25 2018-03-16 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
TWI648272B (zh) 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
WO2014210255A1 (en) * 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors

Also Published As

Publication number Publication date
IL262206A (en) 2018-11-29
EP3461821A1 (en) 2019-04-03
SMT202000317T1 (it) 2020-07-08
MX2020008024A (es) 2022-06-10
AU2019283921B2 (en) 2021-01-07
IL251797A0 (en) 2017-06-29
EA201892207A1 (ru) 2019-02-28
PT3209656T (pt) 2020-06-08
SI3209656T1 (sl) 2020-07-31
MA40301A1 (fr) 2019-03-29
MY188048A (en) 2021-11-12
CA2965517A1 (en) 2016-04-28
IL262206B (en) 2020-07-30
EP3209656A1 (en) 2017-08-30
AR102426A1 (es) 2017-03-01
JP6517928B2 (ja) 2019-05-22
AU2015335694A1 (en) 2017-06-08
KR102001745B1 (ko) 2019-07-18
BR112017007956A2 (pt) 2017-12-19
ZA201804893B (en) 2020-07-29
KR20180132167A (ko) 2018-12-11
CY1123395T1 (el) 2021-12-31
EP3209656B1 (en) 2020-04-01
AU2019283921A1 (en) 2020-01-16
SG11201703188QA (en) 2017-05-30
CN107108583A (zh) 2017-08-29
MX2017005259A (es) 2017-07-26
SMT202000412T1 (it) 2020-09-10
ES2795366T3 (es) 2020-11-23
US20170260160A1 (en) 2017-09-14
HRP20200819T1 (hr) 2020-08-07
MA47043A1 (fr) 2021-03-31
EP3461821B1 (en) 2020-05-13
US10329274B2 (en) 2019-06-25
US20190248760A1 (en) 2019-08-15
US20230192645A1 (en) 2023-06-22
MX393057B (es) 2025-03-24
AR120317A2 (es) 2022-02-09
US10604504B2 (en) 2020-03-31
EA201790740A1 (ru) 2017-08-31
MA40301B1 (fr) 2019-12-31
EA032277B1 (ru) 2019-05-31
UY36371A (es) 2016-04-29
CN107108583B (zh) 2020-11-13
PT3461821T (pt) 2020-08-05
TN2017000119A1 (en) 2018-07-04
SI3461821T1 (sl) 2020-09-30
SG10201903578VA (en) 2019-05-30
TW201900612A (zh) 2019-01-01
JP2017531679A (ja) 2017-10-26
TW201630880A (zh) 2016-09-01
CO2017004481A2 (es) 2017-08-10
SG10201903579SA (en) 2019-05-30
PE20170695A1 (es) 2017-05-26
KR20170061175A (ko) 2017-06-02
US20160115126A1 (en) 2016-04-28
US9802915B2 (en) 2017-10-31
US11623921B2 (en) 2023-04-11
WO2016065226A1 (en) 2016-04-28
CN110511209A (zh) 2019-11-29
MX377837B (es) 2025-03-11
MA47043B1 (fr) 2021-09-30
LT3461821T (lt) 2020-08-10
ES2809974T3 (es) 2021-03-08
US9688629B2 (en) 2017-06-27
RS60312B1 (sr) 2020-07-31
EA034931B1 (ru) 2020-04-08
HUE050706T2 (hu) 2020-12-28
TWI744218B (zh) 2021-11-01
DK3461821T3 (da) 2020-08-17
CY1123401T1 (el) 2021-12-31
PL3209656T3 (pl) 2020-12-14
US20170066740A1 (en) 2017-03-09
TWI743401B (zh) 2021-10-21
TN2018000218A1 (en) 2019-10-04
LT3209656T (lt) 2020-07-27
NZ754113A (en) 2021-02-26
PH12017500725A1 (en) 2017-10-09
PH12017500725B1 (en) 2017-10-09
CN110511209B (zh) 2022-07-05
HRP20201146T1 (hr) 2020-10-30
WO2016065226A8 (en) 2017-04-27
PH12020500265A1 (en) 2021-02-22
ME03740B (me) 2021-01-20
DK3209656T3 (da) 2020-07-13
US9920031B2 (en) 2018-03-20
US20210107891A1 (en) 2021-04-15
KR102030305B1 (ko) 2019-10-08
CL2017000992A1 (es) 2017-11-17
US20190119245A1 (en) 2019-04-25
MY195561A (en) 2023-02-02
US20200165222A1 (en) 2020-05-28
PE20190710A1 (es) 2019-05-17
IL251797B (en) 2020-07-30
NZ731946A (en) 2021-02-26
AU2015335694B2 (en) 2020-04-02
RS60629B1 (sr) 2020-09-30
HUE050592T2 (hu) 2020-12-28
PL3461821T3 (pl) 2020-10-19
CA2965517C (en) 2023-05-02

Similar Documents

Publication Publication Date Title
ME03807B (me) Jedinjenja indol karboksamida korisna kao inhibitori kinaze
HRP20180060T1 (hr) Kondenzirani arilni i heteroarilni laktami
HRP20220899T1 (hr) Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba
JP2014507464A5 (me)
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
PE20190107A1 (es) Sintesis de indazoles
HRP20231048T1 (hr) Derivati bipirazola kao jak inhibitori
JP2015535277A5 (me)
HRP20211583T1 (hr) Tienopiridini i benzotiofeni korisni kao irak4 inhibitori
CO6210771A2 (es) Moduladores 2-aminopirimidina del receptor de histamina h4
HRP20041008B1 (hr) Derivati triazola kao antagonisti receptora tahikinina
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
EA201591429A1 (ru) 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена
FI3689865T3 (fi) Uusia aminopyrimidiinijohdannaisia
AR073687A1 (es) Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras.
JO3809B1 (ar) مركب (6S، 9aS)-N- بنزيل -6-[(4- هيدروكسي فينيل) ميثيل]-4، 7- داي أوكسو -8-({6-[3-(بيبرازين -1- يل) أزيتيدين -1- يل] بيريدين -2- يل} ميثيل)-2-(بروب-2-إين- 1- يل)- أوكتا هيدرو -1H- بيرازينو [2، 1-c][1، 2، 4] ترايازين -1- كربوكساميد
HRP20171031T1 (hr) Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze
AR078303A1 (es) Sulfonas sustituidas que modulan selectivamente el receptor cb2
AR117923A2 (es) Compuestos 4-amino-6-(4-fenilo sustituido)-picolinatos y 6-amino-2-(4-fenilo sustituido)-pirimidin-4-carboxilatos y composición que los comprende
JO3811B1 (ar) مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv
RU2015102057A (ru) НОВЫЕ КОНДЕНСИРОВАННЫЕ ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ с-MET
HRP20140213T1 (hr) Spojevi indazola i pirazolopiridina kao antagonisti ccr1-receptora
MX2012002534A (es) Derivados de (tio) morfolina como moduladores de esfingosin-1-fosfato.
JP2013517279A5 (me)
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов